Login
$SGMT
$10.33 +$0.20 (1.97%) After hours

$SGMT 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027

22 Oct 2026 8-K: Regulation FD Disclosure

Targeting Metabolic Dysfunction with Novel Therapeutics October 2026 Exhibit 99.1

01 Oct 2026 8-K: Entry into a Material Definitive Agreement

As representatives (the “Representatives”) of the several Underwriters

30 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.1 Targeting Metabolic Dysfunction with Novel Therapeutics September 2026

13 Aug 2026 8-K: Other Events

On August 13, 2026, Sagimet Biosciences Inc. (the “Company”) announced that the U.S. Food and Drug Administration cleared the Investigational New Drug application and issued a “Study May Proceed” letter for the Company’s Phase 3 clinical...

11 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S.

21 Jul 2026 8-K: Regulation FD Disclosure

Exhibit 99.1 Targeting Metabolic Dysfunction with Novel Therapeutics July 2026

12 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

03 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER the Sagimet Biosciences inc. 2023 STOCK OPTION AND INCENTIVE PLAN

12 May 2026 8-K: Results of Operations and Financial Condition

Secured equity financing with gross proceeds of $175M in April 2026

28 Apr 2026 8-K: Entry into a Material Definitive Agreement

As representatives (the “Representatives”) of the several Underwriters

27 Apr 2026 8-K: Regulation FD Disclosure

Targeting MetabolicDysfunction with Novel Therapeutics April 2026

27 Apr 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

Targeting MetabolicDysfunction with Novel Therapeutics April 2026 Confidential and proprietary information of Sagimet Biosciences Inc.

21 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

On April 20, 2026, Eduardo Martins, M.D., D.Phil. provided notice to Sagimet Biosciences, Inc. (the “Company”) of his retirement from his role as Chief Medical Officer of the Company, effective as of April 20, 2026. Dr. Martins will cont...

11 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer March 2026

02 Feb 2026 8-K: Regulation FD Disclosure

Targeting MetabolicDysfunction with Novel Therapies to Treat MASH, Acne&Cancer February 2026

18 Dec 2025 8-K: Regulation FD Disclosure; Other Events

Targeting MetabolicDysfunction with Novel Therapies to Treat MASH, Acne&Cancer December 2025

17 Dec 2025 8-K: Other Events

Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program

13 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026

23 Oct 2025 8-K: Regulation FD Disclosure

Targeting MetabolicDysfunction with Novel Therapies to Treat MASH, Acne&Cancer October 2025

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support